Table of Content

1. Market Guides

  • 1.1. Strategic Situation Analysis
  • 1.2. Guide for Executives and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. The Growing Threat and Opportunity of Antimicrobial Resistance
  • 2.2. Defining the Opportunity
    • 2.2.1. Revenue Market Size
  • 2.3. Methods and Sources
    • 2.3.1. Authors
    • 2.3.2. Sources
  • 2.4. U.S. Antibiotic Markets-Perspective
    • 2.4.1. U.S. Outpatient Use of Antibiotics
    • 2.4.2. U.S. Pharmaceutical Spending

3. Overview of a Dynamic Market

  • 3.1. Market Players-Roles & Impacts
    • 3.1.1. Drug manufacturers-Larger/pharmaceutical
    • 3.1.2. Drug manufacturers-Generic
    • 3.1.3. Contract Research and Manufacturing
    • 3.1.4. In Vitro Diagnostics Industry
    • 3.1.5. Drug Marketing Companies
    • 3.1.6. Biotechnology Companies
    • 3.1.7. Regulatory Bodies
  • 3.2. Understanding Antimicrobial Resistance
    • 3.2.1. What is Antimicrobial Resistance (AMR)
    • 3.2.2. Bacteria and Other Microbes
    • 3.2.3. The History of Antibiotics
    • 3.2.4. The Role of Animal Husbandry
    • 3.2.5. The Implications of Horizontal Transfer
    • 3.2.6. The Threat of AMR
  • 3.3. The Changing Road to New Antibiotics & Technologies
  • 3.4. The Key Role of Diagnostics in AMR

4. The Market Opportunity of AMR

  • 4.1. The Key Large Market Opportunities in AMR
    • 4.1.1. Streptococcus Pneumoniae (DRSP)
    • 4.1.2. Campylobacter (DRC)
    • 4.1.3. Clostridium Difficile (CD)
    • 4.1.4. Staphylococcus aureus (MRSA)
    • 4.1.5. Neisseria gonorrhoeae (DRNG)
    • 4.1.6. Salmonella (DRNTS)
  • 4.2. Therapeutic Technology Development Opportunities
    • 4.2.1. Using Viruses Against Bacteria
    • 4.2.2. Hydrolytic Enzymes Join the Fight
    • 4.2.3. Antibodies
    • 4.2.4. Vaccines
    • 4.2.5. Probiotic Technology
    • 4.2.6. Peptides vs. Pathogens
    • 4.2.7. Mining Obsolete Science
    • 4.2.8. CRISPR Antibiotics

5. Antibiotic Resistance Recent Developments

  • 5.1.1. Recent Developments-Importance and How to Use This Section
  • 5.1.2. Importance of These Developments
  • 5.1.3. How to Use This Section
  • 5.2. AMR Pandemic Overlooked
  • 5.3. New resistance-busting antibiotic combination
  • 5.4. CDC Awards $22M to Combat Antimicrobial Resistance
  • 5.5. Antibiotic resistance outwitted by supercomputers
  • 5.6. STIs Reach Record Highs
  • 5.7. New research using nanoparticles to bolster waning antibiotics
  • 5.8. OpGen Receives FDA Clearance for AMR Panel
  • 5.9. CDC Updates STI Diagnosis, Treatment Guidelines
  • 5.10. Positive associations between AM use in animals and AMR in humans
  • 5.11. PEW Antibiotic Pipeline Findings

6. Key Biotechnology Companies and Their Technology

  • 6.1. Melinta Therapeutics
  • 6.2. Arsanis
  • 6.3. Phage Technologies S.A
  • 6.4. Westway Health
  • 6.5. Tetraphase Pharmaceuticals
  • 6.6. BioVersys GmbH
  • 6.7. Nabriva Therapeutics
  • 6.8. Macrolide Pharmaceuticals
  • 6.9. Nemesis Bioscience
  • 6.10. C3J Therapeutics, Inc
  • 6.11. EpiBiome
  • 6.12. discuva
  • 6.13. SmartPhage
  • 6.14. AmpliPhi Biosciences
  • 6.15. Pherecydes Pharma
  • 6.16. Micreos
  • 6.17. Procarta Biosystems
  • 6.18. Lumavita
  • 6.19. Madam Therapeutics
  • 6.20. Priaxon
  • 6.21. Biolytx Pharmaceuticals
  • 6.22. AntibioTx
  • 6.23. Xellia Pharmaceutials
  • 6.24. Paratek Pharmaceuticals
  • 6.25. Synereca Pharmaceuticals
  • 6.26. Allecra Therapeutics
  • 6.27. Fixed Phage
  • 6.28. Enanta Pharmaceuticals, Inc.
  • 6.29. Demuris
  • 6.30. Prommune
  • 6.31. Biosergen
  • 6.32. Innovation Pharmaceuticals
  • 6.33. Aviragen Therapeutics
  • 6.34. Achillion Pharmaceuticals
  • 6.35. ImmunNovative Developments, S.L.
  • 6.36. Achaogen, Inc.
  • 6.37. SelectX Pharmaceuticals, Inc.
  • 6.38. TaiGen Biotechnology Co., Ltd.
  • 6.39. Theravance Biopharma
  • 6.40. Abbvie
  • 6.41. KYORIN Pharmaceutical Co.,Ltd.
  • 6.42. Iterum Therapeutics Limited
  • 6.43. Forge Therapeutics
  • 6.44. Alopexx Vaccine LLC
  • 6.45. Integrated Biotherapeutics
  • 6.46. Hennepin Life Sciences
  • 6.47. Fedora Pharmaceuticals Inc.
  • 6.48. Contrafect Corporation
  • 6.49. Basilea Pharmaceutica Ltd.
  • 6.50. AiCuris
  • 6.51. RedHill Biopharma
  • 6.52. Redx Pharma Plc/ Redx Anti Infectives Ltd.
  • 6.53. ABAC Therapeutics
  • 6.54. Alaxia SAS
  • 6.55. Antabio S.A.S
  • 6.56. Auspherix Ltd
  • 6.57. BioFilm Pharma
  • 6.58. Centauri Therapeutics Ltd
  • 6.59. Combioxin SA
  • 6.60. Da Volterra
  • 6.61. Debiopharm International SA
  • 6.62. Deinobiotics/Deinove
  • 6.63. Destiny Pharma plc
  • 6.64. Eligo Bioscience
  • 6.65. Helperby Therapeutics Ltd
  • 6.66. Karveel Pharmaceuticals
  • 6.67. MaaT Pharma
  • 6.68. Motif BioSciences, Inc / Motif Bio PLC
  • 6.69. Mutabilis SAS
  • 6.70. Neem Biotech Ltd
  • 6.71. Northern Antibiotics Oy (Ltd)
  • 6.72. Nosopharm
  • 6.73. NovaBiotics Ltd
  • 6.74. Phico Therapeutics Ltd
  • 6.75. Polyphor Ltd
  • 6.76. QureTech Bio AB
  • 6.77. SetLance srl
  • 6.78. Ultupharma AB
  • 6.79. Vaxdyn
  • 6.80. Vibiosphen
  • 6.81. Bioaster
  • 6.82. Vivexia
  • 6.83. KBP Biosciences
  • 6.84. Absynth Biologics
  • 6.85. Spero Therapeutics
  • 6.86. Merck
  • 6.87. Symphogen
  • 6.88. Warp Drive Bio
  • 6.89. Johnson & Johnson (Janssen)
  • 6.90. Pfizer
  • 6.91. Allergan
  • 6.92. GlaxoSmithKline
  • 6.93. Novartis
  • 6.94. Gilead Sciences
  • 6.95. AstraZeneca
  • 6.96. Sanofi
  • 6.97. Shionogi Inc.
  • 6.98. Cipla
  • 6.99. DSM Sinochem Pharmaceuticals
  • 6.100. Wockhardt Ltd.
  • 6.101. VenatoRx Pharmaceuticals
  • 6.102. MicuRx
  • 6.103. Entasis Therapeutics
  • 6.104. Merlion Pharmaceuticals
  • 6.105. Aridis Pharmaceuticals Inc.
  • 6.106. The Therapeutics Race-Summary of Companies Research Areas

7. Global Market Size

  • 7.1. Global Market by Country
  • 7.2. Global Market by Pathogen
  • 7.3. Global Market by Technology

8. Market Sizes by Pathogen

  • 8.1. DRSP Market
  • 8.2. DRC Market
  • 8.3. CD Market
  • 8.4. MRSA Market
  • 8.5. DRNG Market
  • 8.6. DRNTS Market
  • 8.7. Other Pathogen Market

9. Market Sizes by Technology

  • 9.1. Antibiotics Market
  • 9.2. Phage Market
  • 9.3. Pep/Lys Market
  • 9.4. Antibodies Market
  • 9.5. Vaccine Market
  • 9.6. Other Technology Market

10. The Future of AMR

11. Appendices

  • 11.1. United States Medicare System: Top Selling Drugs 2011-2015

Table of Tables

  • Table 1: USA-Outpatient Use of Antibiotics by Class
  • Table 2: USA-Outpatient Use of Antibiotics Top 5
  • Table 3: Market Players by Type
  • Table 4: Known Human Pathogenic Diseases
  • Table 5: The Key Market Opportunities
  • Table 6:-Market Potential DRSP Therapeutic
  • Table 7:-Market Potential DRC Therapeutic
  • Table 8: Eight Technologies under development
  • Table 9: Antibodies Approved for Infectious Disease Treatment
  • Table 10: Therapeutic Technology Research-# of Companies
  • Table 11: Global Market by Country
  • Table 12: Global Market by Pathogen
  • Table 13: Global Market by Technology
  • Table 14: DRSP Segment by Country
  • Table 15: DRC Segment by Country
  • Table 16: CD Segment by Country
  • Table 17: MRSA Segment by Country
  • Table 18: DRNG Segment by Country
  • Table 19: DRNTS Segment by Country
  • Table 20: Other Pathogen Segment by Country
  • Table 21: Antibiotics Segment by Country
  • Table 22: Phage Segment by Country
  • Table 23: Pep/Lys Segment by Country
  • Table 24: Antibodies Segment by Country
  • Table 25: Vaccine Segment by Country
  • Table 26: Other Technology Segment by Country
  • Table 27: 2011 to 2015 Top Selling Drugs

Table of Figures

  • Figure 1: Pharmaceutical Spending Trends
  • Figure 2: AMR and Antibiotic Introduction
  • Figure 3: The Death Toll of AMR
  • Figure 4: Phage T4 Anatomy and Infection Cycle
  • Figure 5: Key Global Markets
  • Figure 6: Pathogen Share by Year
  • Figure 7: Pathogen Segment Growth Rates
  • Figure 8: Segment Share Shifts
  • Figure 9: Market Share Start Year
  • Figure 10: Market Share End Year
  • Figure 11: Technology Share by Year
  • Figure 12: Pathogen Segment Growth Rates
  • Figure 13: Segment Share Shifts
  • Figure 14: Market Share Start Year
  • Figure 15: Market Share End Year
  • Figure 16: DRSP vs. Total Market Growth
  • Figure 17: DRC vs. Total Market Growth
  • Figure 18: CD vs. Total Market Growth
  • Figure 19: MRSA vs. Total Market Growth
  • Figure 20: DRNG vs. Total Market Growth
  • Figure 21: DRNTS vs. Total Market Growth
  • Figure 22: Other Pathogen vs. Total Market Growth
  • Figure 23: Antibiotics vs. Total Market Growth
  • Figure 24: Phage vs. Total Market Growth
  • Figure 25: Pep/Lys vs. Total Market Growth
  • Figure 26: Antibodies vs. Total Market Growth
  • Figure 27: Vaccine vs. Total Market Growth
  • Figure 28: Other Technology vs. Total Market Growth